These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 29173192)

  • 1. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The development of biosimilars in oncology].
    Jiang SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A descriptive analysis of real-world oncology biosimilar use in Japan.
    Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C
    Future Oncol; 2024; 20(25):1837-1850. PubMed ID: 38864611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
    Busse A; Lüftner D
    Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: Implications for Clinical Practice.
    Rifkin RM; Peck SR
    J Oncol Pract; 2017 Sep; 13(9_suppl):24s-31s. PubMed ID: 28898593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar medicines used for cancer therapy in Europe: a review.
    Santos SB; Sousa Lobo JM; Silva AC
    Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
    Rioufol C; Salles G
    Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
    Zelenetz AD
    J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1424-1426. PubMed ID: 31766021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
    Xue X; Truong B; Qian J
    Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
    Trollope R; Johnson S; Ireland H
    Immunotherapy; 2017 Jun; 9(7):527-529. PubMed ID: 28523951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar monoclonal antibodies (mAbs) in oncology.
    Moore C
    Br J Nurs; 2017 Sep; 26(16):S26-S32. PubMed ID: 28880625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies in oncology.
    Levene AP; Singh G; Palmieri C
    J R Soc Med; 2005 Apr; 98(4):146-52. PubMed ID: 15805554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.